Menu Search
Equities

Dermapharm Holding SE

0A5J:LSE

Dermapharm Holding SE

Actions
  • Price (EUR)37.60
  • Today's Change0.375 / 1.01%
  • Shares traded11.78k
  • 1 Year change-5.79%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 17:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Dermapharm Holding SE had net income fall -53.54% from 134.24m to 62.37m despite a 10.79% increase in revenues from 1.02bn to 1.14bn. An increase in the selling, general and administrative costs as a percentage of sales from 28.39% to 36.87% was a component in the falling net income despite rising revenues.
Gross margin64.66%
Net profit margin7.71%
Operating margin17.78%
Return on assets4.17%
Return on equity16.04%
Return on investment5.01%
More ▼

Cash flow in EURView more

In 2023, Dermapharm Holding SE increased its cash reserves by 5.10%, or 7.71m. The company earned 218.60m from its operations for a Cash Flow Margin of 19.25%. In addition the company generated 204.54m cash from financing while 415.43m was spent on investing.
Cash flow per share3.49
Price/Cash flow per share10.73
Book value per share10.84
Tangible book value per share-9.56
More ▼

Balance sheet in EURView more

Dermapharm Holding SE has a Debt to Total Capital ratio of 63.52%, a lower figure than the previous year's 189.49%.
Current ratio1.66
Quick ratio0.7368
Total debt/total equity1.76
Total debt/total capital0.6352
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)52.30%
EPS growth(5 years)-3.86
EPS (TTM) vs
TTM 1 year ago		-4.72
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.